LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine

Photo from wikipedia

EJD, vol. 32, n◦ 3, May-June 2022 escape mechanism in SS [7]. Furthermore, the receptor for CCL3 and CCR4 is found on tumour cells and regulatory T cells and is… Click to show full abstract

EJD, vol. 32, n◦ 3, May-June 2022 escape mechanism in SS [7]. Furthermore, the receptor for CCL3 and CCR4 is found on tumour cells and regulatory T cells and is particularly involved in the development of SS [7, 8]. Finally, the observed decrease in CXCL10 could be responsible for the loss of Sézary cell epidermotropism and their consequential presence in the blood [8, 9]. Inhibition of one immune pathway may result in an imbalance in cytokine production and cause, in susceptible patients, paradoxical activation of other immune pathways responsible for inflammatory or neoplastic processes. Dedicated studies are needed to establish a causal link between IL-5 inhibition and the immunological alterations that may have contributed to the development of SS in our patient. Our observation is proof of the need for caution regarding the use of rapidly emerging cytokine pathway inhibitors, the immunological consequences of which remain poorly understood.

Keywords: bnt162b2 covid; second dose; dose bnt162b2; psoriatic arthritis; flare second; arthritis flare

Journal Title: European Journal of Dermatology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.